Regulatory Context

Research Peptide vs Compounding Pharmacy

The difference between a "research peptide" and a "compounding pharmacy peptide" is the legal, labeling, and regulatory pathway. It is not a purity contest. A clean HPLC result on an RUO vial does not make it a compounded drug.

Regulatory context, not product recommendation

Short answer

"Research Use Only" (RUO) products are sold for laboratory research and are not labeled or intended for human use. Compounding pharmacy preparations are made pursuant to a prescription under section 503A of the FD&C Act, dispensed to a specific patient, and subject to state pharmacy board oversight. The FDA also recognizes 503B outsourcing facilities that can compound without patient-specific prescriptions under cGMP requirements. The distinction is legal and regulatory, not a statement about analytical purity or which source is "better."

Pathway comparison

Research Use Only (RUO)

For research use only — not for human use

Labeling: Typically labeled 'For research use only' or 'Not for human consumption.'
Oversight: Not subject to FDA drug approval process. No prescription required for purchase.
Documentation: May include COA with purity, identity, and other analytical results. No prescription or dispensing record.
Notes: A clean HPLC result on an RUO vial does not make it a compounded drug. The labeling and intended use are different. RUO products are commonly sold as lyophilized (freeze-dried) powder.

503A Compounding Pharmacy

Patient-specific compounded preparation

Labeling: Dispensed with a prescription, labeled with patient name, prescriber, pharmacy, lot, beyond-use date.
Oversight: Regulated under state pharmacy boards and FDA 503A. Requires a valid prescription for a specific patient.
Documentation: Prescription record, dispensing label, pharmacy lot, beyond-use date. May include COA or testing records.
Notes: 503A preparations are typically dispensed as ready-to-use liquid, not lyophilized powder. The pharmacy does the reconstitution and assigns a beyond-use date.

503B Outsourcing Facility

Bulk compounding without patient-specific prescription

Labeling: Labeled with facility information, lot, expiration, and compound details. Not patient-specific.
Oversight: Registered with FDA under 503B. Subject to FDA inspection and cGMP requirements. Does not require a patient-specific prescription.
Documentation: Facility registration, lot records, FDA inspection history. May supply healthcare facilities directly.
Notes: 503B facilities can compound in larger quantities for office use or hospital stock. They are not the same as 503A patient-specific pharmacies.

The FDA Human Drug Compounding hub provides context on sterile compounding requirements. Compounding sterile preparations involves more than combining ingredients; it includes environmental controls, technique, and documentation that differ from laboratory reconstitution of an RUO vial.

Units vs milligrams: why the vial number confuses people

Some peptide vials are labeled in milligrams (mg). Others are labeled in units (U or IU). These measure different things. Milligrams measure mass. Units measure biological activity, as defined for a specific substance.

Insulin, for example, has a standardized unit definition: one unit of insulin lowers blood glucose by an expected amount under specific conditions. The unit is defined by biological effect, not by milligrams. Other peptides may not have an established unit definition at all.

When someone asks "how many units is 10 mg," the answer depends entirely on what substance they are talking about and whether that substance has a defined unit. There is no universal conversion factor. If the label says milligrams and the instructions say units, ask the prescriber or pharmacist to clarify. Do not guess.

A COA does not change the regulatory category

A certificate of analysis (COA) can show analytical results for a sample: identity, purity, sterility, endotoxin, and other tests. It is useful documentation. But a COA showing high purity does not convert an RUO product into a compounded drug. The regulatory category is determined by the manufacturing, labeling, prescription pathway, and intended use, not by the purity number alone. The Peptide App indexes COA observations and pricing; it does not certify either channel.

Does "research use only" protect me?

A "research use only" or "not for human consumption" label describes the seller's claimed intended use. It does not convert the product into an approved drug, a compounded drug, or a legal shield for the buyer or seller.

FDA determines intended use from the whole picture of labeling, advertising, and circumstances of distribution — not from the disclaimer text alone. Under 21 CFR 201.128, objective intent may be shown by labeling claims, advertising matter, oral or written statements, or circumstances in which the article is offered or used for a purpose it is neither labeled nor advertised for.

If the totality of how a product is marketed suggests it is intended for human use, the label disclaimer does not override that conclusion. An RUO label on a vial sold through channels that imply human consumption does not automatically become a defense to an enforcement action. This is not legal advice; it is regulatory context. The FDA compounding Q&A provides additional background on how compounding requirements apply.

Is BPC-157 compoundable? What is the 503A bulks list?

Under section 503A of the FD&C Act, compounding pharmacies may only use bulk drug substances that: (1) have an applicable USP or NF monograph, (2) are components of FDA-approved drug products, or (3) appear on FDA's Section 503A bulk drug substances list. Injectable BPC-157, TB-500, KPV, and MOTS-c do not meet the first two criteria, so they would need to be on the bulks list to qualify.

FDA develops the bulks list through notice-and-comment rulemaking after consulting the Pharmacy Compounding Advisory Committee (PCAC). A PCAC recommendation is advice to FDA, not a final rule. A substance is not on the list until FDA completes the rulemaking process and publishes a final rule in the Federal Register.

On July 23–24, 2026 (docket FDA-2025-N-6895), PCAC met to consider several peptides. The meeting page shows the indication-specific uses FDA evaluated: BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing, MOTS-c for obesity and osteoporosis, Emideltide for opioid withdrawal/insomnia/narcolepsy, Semax for cerebral ischemia/migraine/trigeminal neuralgia, and Epitalon for insomnia. These were the nominated and reviewed uses — not every community use people associate with these peptides.

PCAC voted to recommend inclusion for BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax. PCAC voted against recommending Emideltide. FDA staff had recommended against all substances under the applicable evaluation criteria. The PCAC recommendations are advisory; FDA is not bound to follow them and must still complete rulemaking. If you read that "PCAC recommended BPC-157," note that the reviewed use was ulcerative colitis — the recommendation, if it leads to listing, does not transfer to sports-injury stacks or tissue-repair claims.

As of this writing, BPC-157, TB-500, KPV, and MOTS-c are not on the 503A bulks list. A recommendation is not a rule. If you see "PCAC approved BPC-157" or similar phrasing, that conflates a committee recommendation with a legal change that has not occurred.

Category 1 of FDA's interim policy (which historically allowed compounding of certain nominated substances pending evaluation) applied to substances like non-injectable GHK-Cu. That category is a contrast showing how the interim policy worked, not a shopping list. Substances nominated on or after January 7, 2025 are not placed into the interim categories.

Questions people ask

What does RUO mean on a peptide vial?

RUO stands for 'Research Use Only.' It indicates the product is sold for laboratory research and is not intended for human use, diagnosis, or treatment. RUO labeling is a regulatory classification, not a purity specification.

Is a research peptide less pure than a compounded one?

Not necessarily. Purity is an analytical measurement, not a regulatory category. An RUO vial can have high purity and a clean COA. A compounded preparation can also have high purity. The difference is the legal pathway, not a purity contest. COAs from either source still need to be read with chain-of-custody and testing context in mind.

What is the difference between 503A and 503B compounding?

503A compounding pharmacies prepare patient-specific medications under a prescription, regulated by state pharmacy boards. 503B outsourcing facilities can compound in bulk without patient-specific prescriptions, are FDA-registered, and must follow cGMP requirements. 503A is prescription-based; 503B is facility-based.

What is a 503A compounding pharmacy?

A 503A compounding pharmacy prepares patient-specific medications pursuant to a valid prescription under section 503A of the Federal Food, Drug, and Cosmetic Act. The preparation is made for an individual patient based on a prescriber's order, subject to state pharmacy board oversight.

Why is research peptide powder and compounded peptide liquid?

RUO peptides are commonly sold as lyophilized (freeze-dried) powder for stability and shelf life. The buyer reconstitutes it. 503A compounding pharmacies typically dispense ready-to-use liquid because they perform the reconstitution, assign a beyond-use date, and prepare it for the specific patient. The physical form reflects the supply chain, not the molecule.

Can I use a research peptide instead of a compounded one?

That is a legal, regulatory, and medical question, not a chemistry question. RUO products are not labeled or intended for human use. Whether to use them is a decision that involves the legal context, prescriber guidance, sourcing, testing, and personal risk assessment. This guide does not recommend either pathway.

Why are some peptide vials labeled in 'units' and some in 'milligrams'?

Units and milligrams measure different things. Milligrams measure mass. Units measure biological activity as defined for a specific substance. Some peptides (like insulin and certain hormones) have established unit definitions. Others are sold by mass (milligrams). The two are not interchangeable, and conversion requires knowing the specific substance and its unit definition.

How do I convert units to milligrams?

You cannot convert units to milligrams without knowing the substance-specific definition. For example, insulin has a defined unit based on biological activity. Other peptides may not have a standardized unit definition at all. If a vial says '10 mg' and you are looking for 'units,' ask the prescriber or pharmacist what the intended measure is.

Does a research-use-only label mean a peptide is legal to use?

No. An RUO or 'not for human consumption' label describes the seller's claimed intended use. It does not convert the product into an approved drug, a compounded drug, or a legal shield. FDA determines intended use from the whole picture — labeling, advertising, and distribution circumstances — not from the disclaimer text alone. See 21 CFR 201.128.

Is BPC-157 on the 503A bulks list?

No. As of this writing, BPC-157 is not on the FDA's Section 503A bulk drug substances list. The Pharmacy Compounding Advisory Committee (PCAC) voted to recommend its inclusion on July 23, 2026, but a committee recommendation is not a final rule. Until FDA completes notice-and-comment rulemaking and publishes a final rule, BPC-157 is not a listed 503A bulk.

Did PCAC make BPC-157 legal to compound?

No. PCAC is an advisory committee that makes recommendations to FDA. On July 23, 2026, PCAC voted to recommend adding BPC-157 to the 503A bulks list. That recommendation is not binding on FDA and does not change the law. FDA must still propose a rule, collect public comments, and issue a final rule before BPC-157 can appear on the list.

Is BPC-157 legal after the July 2026 PCAC vote?

No. The July 2026 PCAC recommendation does not change BPC-157's legal status. The recommendation is advice, not law. Additionally, the use evaluated by PCAC was ulcerative colitis — not sports injury, tissue repair, or other community uses people associate with BPC-157. Even if FDA eventually finalizes listing, the bulks-list pathway is about compounding-pharmacy eligibility, not approval for any use.

Are TB-500, KPV, and MOTS-c on the 503A bulks list?

No. Like BPC-157, these peptides received favorable PCAC recommendations in July 2026 but are not on the 503A bulks list until FDA completes rulemaking. They are not components of FDA-approved drugs and do not have USP monographs, so they are not 503A-eligible through other pathways. The recommendation is a step in a process, not the outcome.

How to read a peptide COA Peptide COA database Peptide pricing index How to reconstitute peptides

Sources used for context

Educational disclaimer

This guide is for educational purposes only. It does not recommend specific products, sources, or pathways. The legal and regulatory landscape varies by jurisdiction and changes over time. Consult a licensed professional for guidance on obtaining and using any medication or research product. The Peptide App does not sell peptides and does not certify either research or compounding sources.